Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Inspire Medical Systems Q3 2026 Results: Net Loss of $24.4M

For the nine months ended September 30, 2026, Inspire Medical Systems reported a net loss of $35.4 million on revenue of $611.9 million, compared to a net profit of $9.3 million in the prior year period. The shift to a loss was driven by a decrease in revenue and a significant increase in selling, general, and administrative expenses.

Watch the Inspire Medical Systems, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue206.7224.5
Gross profit177.9192.7
Profit before tax-25.013.6
Net income-24.49.9
EPS (diluted, $ a share)$-0.84$0.34

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-7.9%
Gross margin86.0%
Operating margin-13.9%
Source

10-Q filed with the SEC, NYSE: INSP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Inspire Medical Systems, Inc.: key numbers

Share price
$59.12Close, Nov 16
Market cap
$1.71B
Shares outstanding
28.97MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Inspire Medical Systems, Inc.

All →
4:30 PM ET 8-K
Financial Results

Inspire Medical Systems Financial Results

Inspire Medical Systems reported Q3 2026 revenue of $206.7 million, a 7.9% decrease year-over-year primarily due to U.S. coding and reimbursement challenges. Despite the revenue decline, the company achieved a positive adjusted diluted EPS of $0.14 and noted that the AMA approved new Category I CPT codes for its Inspire V system effective 2028.

Term
3 months

“We are pleased to have delivered sequential growth in the third quarter, with U.S. performance coming in ahead of our expectations. Results suggest that, despite some lingering headwinds, there is greater comfort among implanting physicians with the current coding dynamic.”

Tim Herbert, Chairman and CEO of Inspire Medical Systems

“Looking further ahead, we were also pleased with the AMA Editorial Panel’s September approval of a new CPT® code for single lead HGNS devices, including the Inspire V system. When this takes effect in January 2028, a dedicated code set will give physicians and hospitals enhanced clarity around coding and reimbursement and, in turn, further enable patient access to Inspire therapy.”

Tim Herbert, Chairman and CEO of Inspire Medical Systems

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.